Novo Nordisk submits application in the EU for including data from the DEVOTE trial in the Tresiba® label

Bagsværd, Denmark, 14 June 2017 - Novo Nordisk today announced the submission of a Type II Variation application to the European Medicines Agency (EMA) for including data in the label for Tresiba^® (insulin degludec) from the DEVOTE trial, a long-term, randomised, double-blinded and event-driven trial conducted to confirm the cardiovascular safety of Tresiba^® compared to insulin glargine U100 when added to standard of care, in people with type 2 diabetes.

Further information

Media:
Katrine Sperling	[phone]	[e-mail]
Ken Inchausti (US)	[phone]	[e-mail]
Investors:
Peter Hugreffe Ankersen	[phone]	[e-mail]
Hanna Ögren	[phone]	[e-mail]
Anders Mikkelsen	[phone]	[e-mail]
Kasper Veje (US)	[phone]	[e-mail]

Company announcement No 44/2017

Company announcement No 44/2017

---

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire